In the latest development in a two-year, high-stakes legal battle, the European Commission has ordered U.S. biotech company Illumina to sell a startup it acquired in 2021 while EU antitrust officials were still scrutinizing the $8 billion deal over competition concerns. 

Illumina acquired Grail, a U.S.-based startup that develops blood-based early cancer detection tests, while the Commission’s investigation was ongoing, in violation of EU merger control rules. The EU’s investigation concluded with a merger veto from officials in 2022.

This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.

To view this content, please continue to their sites.

Not a Lexis Subscriber?
Subscribe Now

Not a Bloomberg Law Subscriber?
Subscribe Now

Why am I seeing this?

LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.

For questions call 1-877-256-2472 or contact us at [email protected]